Alex Thompson CFA
Stock Analyst at Stifel Nicolaus
(4.98)
# 47
Out of 4,575 analysts
271
Total ratings
73.2%
Success rate
49.3%
Average return
Main Sectors:
Stocks Rated by Alex Thompson CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLDX Celldex Therapeutics | Maintained: Buy | $68 | $35.28 | +92.74% | 7 | Jul 22, 2026 | |
| ALMS Alumis | Maintained: Buy | $44 | $28.00 | +57.14% | 5 | Jul 9, 2026 | |
| CRNX Crinetics Pharmaceuticals | Downgraded: Hold | $83 → $85 | $83.73 | +1.52% | 13 | Jul 8, 2026 | |
| PALI Palisade Bio | Maintained: Buy | $5 | $1.95 | +156.41% | 4 | Jul 6, 2026 | |
| EVMN Evommune | Maintained: Buy | $54 | $11.36 | +375.35% | 2 | Jul 6, 2026 | |
| VRDN Viridian Therapeutics | Maintained: Buy | $39 → $40 | $19.27 | +107.58% | 18 | Jun 30, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $150 | $92.16 | +62.76% | 10 | Jun 29, 2026 | |
| ARGX argenx SE | Maintained: Buy | $1,255 | $918.22 | +36.68% | 29 | Jun 29, 2026 | |
| APGE Apogee Therapeutics | Maintained: Buy | $135 → $133 | $134.28 | -0.95% | 15 | Jun 29, 2026 | |
| SYRE Spyre Therapeutics | Reiterated: Buy | $107 | $102.13 | +4.77% | 18 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $28 | $17.10 | +63.74% | 6 | Jun 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $2.49 | +100.80% | 2 | May 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $49 | $39.41 | +24.33% | 16 | May 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $36 → $39 | $18.44 | +111.50% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $332 → $328 | $253.86 | +29.21% | 16 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $2 → $4 | $5.23 | -23.52% | 13 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $40 | $20.08 | +99.20% | 2 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $43 | $57.36 | -25.03% | 29 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $43 | $33.10 | +29.91% | 1 | May 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $65 → $120 | $103.87 | +15.53% | 11 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $85 | $54.15 | +56.97% | 11 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $13 → $19 | $19.02 | -0.11% | 8 | Mar 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $68 → $114 | $110.57 | +3.10% | 9 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $3 | $1.09 | n/a | 17 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $23 | $11.19 | n/a | 2 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $34 | $40.74 | n/a | 1 | Aug 8, 2023 |
Celldex Therapeutics
Jul 22, 2026
Maintained: Buy
Price Target: $68
Current: $35.28
Upside: +92.74%
Alumis
Jul 9, 2026
Maintained: Buy
Price Target: $44
Current: $28.00
Upside: +57.14%
Crinetics Pharmaceuticals
Jul 8, 2026
Downgraded: Hold
Price Target: $83 → $85
Current: $83.73
Upside: +1.52%
Palisade Bio
Jul 6, 2026
Maintained: Buy
Price Target: $5
Current: $1.95
Upside: +156.41%
Evommune
Jul 6, 2026
Maintained: Buy
Price Target: $54
Current: $11.36
Upside: +375.35%
Viridian Therapeutics
Jun 30, 2026
Maintained: Buy
Price Target: $39 → $40
Current: $19.27
Upside: +107.58%
Oruka Therapeutics
Jun 29, 2026
Maintained: Buy
Price Target: $150
Current: $92.16
Upside: +62.76%
argenx SE
Jun 29, 2026
Maintained: Buy
Price Target: $1,255
Current: $918.22
Upside: +36.68%
Apogee Therapeutics
Jun 29, 2026
Maintained: Buy
Price Target: $135 → $133
Current: $134.28
Upside: -0.95%
Spyre Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $107
Current: $102.13
Upside: +4.77%
Jun 8, 2026
Maintained: Buy
Price Target: $28
Current: $17.10
Upside: +63.74%
May 28, 2026
Reiterated: Buy
Price Target: $5
Current: $2.49
Upside: +100.80%
May 25, 2026
Maintained: Buy
Price Target: $49
Current: $39.41
Upside: +24.33%
May 15, 2026
Maintained: Buy
Price Target: $36 → $39
Current: $18.44
Upside: +111.50%
May 8, 2026
Maintained: Buy
Price Target: $332 → $328
Current: $253.86
Upside: +29.21%
May 8, 2026
Maintained: Hold
Price Target: $2 → $4
Current: $5.23
Upside: -23.52%
May 7, 2026
Maintained: Buy
Price Target: $40
Current: $20.08
Upside: +99.20%
May 5, 2026
Maintained: Hold
Price Target: $43
Current: $57.36
Upside: -25.03%
May 1, 2026
Initiated Coverage: Buy
Price Target: $43
Current: $33.10
Upside: +29.91%
Mar 10, 2026
Maintained: Buy
Price Target: $65 → $120
Current: $103.87
Upside: +15.53%
Mar 5, 2026
Maintained: Buy
Price Target: $56 → $85
Current: $54.15
Upside: +56.97%
Mar 1, 2026
Maintained: Hold
Price Target: $13 → $19
Current: $19.02
Upside: -0.11%
Dec 15, 2025
Maintained: Buy
Price Target: $68 → $114
Current: $110.57
Upside: +3.10%
Mar 3, 2025
Downgraded: Hold
Price Target: $32 → $3
Current: $1.09
Upside: n/a
Nov 7, 2024
Reiterated: Buy
Price Target: $23
Current: $11.19
Upside: n/a
Aug 8, 2023
Initiated Coverage: Buy
Price Target: $34
Current: $40.74
Upside: n/a